AU742365B2 - Adenoviral vectors with modified tropism - Google Patents

Adenoviral vectors with modified tropism Download PDF

Info

Publication number
AU742365B2
AU742365B2 AU64629/98A AU6462998A AU742365B2 AU 742365 B2 AU742365 B2 AU 742365B2 AU 64629/98 A AU64629/98 A AU 64629/98A AU 6462998 A AU6462998 A AU 6462998A AU 742365 B2 AU742365 B2 AU 742365B2
Authority
AU
Australia
Prior art keywords
receptor
fgf
antibody
fragment
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU64629/98A
Other languages
English (en)
Other versions
AU6462998A (en
Inventor
Andrew Baird
David T Curiel
Joanne T. Douglas
Glenn F. Pierce
Buck E. Rogers
Barbara A Sosnowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Selective Genetics Inc
Original Assignee
UAB Research Foundation
Selective Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, Selective Genetics Inc filed Critical UAB Research Foundation
Publication of AU6462998A publication Critical patent/AU6462998A/en
Priority to AU91408/01A priority Critical patent/AU771686B2/en
Application granted granted Critical
Publication of AU742365B2 publication Critical patent/AU742365B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AU64629/98A 1997-03-14 1998-03-13 Adenoviral vectors with modified tropism Ceased AU742365B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU91408/01A AU771686B2 (en) 1997-03-14 2001-11-19 Adenoviral vectors with modified tropism

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4078297P 1997-03-14 1997-03-14
US60/040782 1997-03-14
US6526597P 1997-11-10 1997-11-10
US60/065265 1997-11-10
PCT/US1998/004964 WO1998040508A1 (en) 1997-03-14 1998-03-13 Adenoviral vectors with modified tropism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU91408/01A Division AU771686B2 (en) 1997-03-14 2001-11-19 Adenoviral vectors with modified tropism

Publications (2)

Publication Number Publication Date
AU6462998A AU6462998A (en) 1998-09-29
AU742365B2 true AU742365B2 (en) 2002-01-03

Family

ID=26717429

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64629/98A Ceased AU742365B2 (en) 1997-03-14 1998-03-13 Adenoviral vectors with modified tropism

Country Status (6)

Country Link
US (2) US6613563B1 (https=)
EP (1) EP0973926A1 (https=)
JP (1) JP2001515493A (https=)
AU (1) AU742365B2 (https=)
CA (1) CA2283461A1 (https=)
WO (1) WO1998040508A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687117B2 (en) * 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US20060275261A1 (en) * 1993-10-25 2006-12-07 Canji, Inc. Adenoviral vectors having a protein IX deletion
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US20010006629A1 (en) * 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
US7060433B1 (en) 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
DE19845434C1 (de) * 1998-10-02 2000-03-16 Juergen Schrader Gewebebindende Peptide, ihre Identifizierung, Herstellung und Verwendung
ATE483816T1 (de) * 1998-11-19 2010-10-15 Univ Georgetown Systemisches virus/ligand genabgabemittel und gentherapie
AU5011200A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in hematopoietic cells
EP1223952B1 (en) * 1999-10-07 2008-04-16 Carlos Estuardo Aguilar-Cordova Methods for treatment of solid tumors and metastasis by gene therapy
AU1194501A (en) * 1999-10-14 2001-04-23 Wistar Institute, The Inhibition of tumorigenic properties of melanoma cells
AU2001234981A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
AU2001237256A1 (en) * 2000-03-08 2001-09-17 Neurosearch A/S A method of sensitising endothelial cells to prodrugs
IL153853A0 (en) * 2000-07-10 2003-07-31 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
US7306792B2 (en) * 2001-03-27 2007-12-11 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
DE60234100D1 (de) * 2001-04-24 2009-12-03 Vlaams Interuniv Inst Biotech Verwendung von "hypoxia inducible factor 2alpha" zur behandlung von "neonatal respiratory distress syndrome"
JP2002335965A (ja) * 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
WO2002103004A1 (en) * 2001-06-15 2002-12-27 The Children's Hospital Of Philadelphia Surface modification for improving biocompatibility
KR100996226B1 (ko) * 2001-10-31 2010-11-24 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
US20030133912A1 (en) * 2001-12-11 2003-07-17 Davidson Beverly L. Receptor-targeted adenoviral vectors
FR2842823A1 (fr) * 2002-07-25 2004-01-30 Inst Nat Sante Rech Med Adenovirus modifies pour le ciblage des lymphocytes b
US7033333B1 (en) * 2002-08-02 2006-04-25 Arthur Croft Self actuated cervical (neck) traction device
WO2004029581A2 (en) * 2002-09-26 2004-04-08 The Children's Hospital Of Philadelphia Method of determining surface binding capacity
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
US20070098702A1 (en) * 2005-02-17 2007-05-03 University Of Maryland, Baltimore Recombinant protein polymer vectors for systemic gene delivery
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
WO2006130690A2 (en) * 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7858356B2 (en) 2005-11-24 2010-12-28 Genomidea, Inc. Mutant paramyxovirus and method for production thereof
US7659999B2 (en) * 2005-12-23 2010-02-09 Xerox Corporation UIdesign: N-up calculator user interface
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
WO2008128251A1 (en) 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
WO2009137689A2 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
US8389804B2 (en) 2010-04-08 2013-03-05 University Of Florida Research Foundation, Inc. Viral based transient-expression vector system that allows multiple applications
CN102933713B (zh) * 2010-04-08 2015-05-13 佛罗里达大学研究基金会有限公司 具有多功能的瞬时表达病毒载体体系
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
US10947282B2 (en) 2015-01-19 2021-03-16 The Texas A & M University System Functionalized protein-based materials and their uses
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
EP3625714B1 (en) 2017-05-16 2021-03-17 Life Technologies Corporation Methods for compression of molecular tagged nucleic acid sequence data
US20220340627A1 (en) * 2019-09-20 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Dach1 builds artery networks that protect against cardiac injury in adults

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005266A1 (en) * 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
WO1992011033A1 (en) * 1990-12-20 1992-07-09 Arch Development Corporation Control of gene expression by ionizing radiation
DE69333115D1 (de) * 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
WO1994026892A1 (en) * 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
US6312699B1 (en) 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005266A1 (en) * 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.T. DOUGLAS NATURE BIOTECHNOLOGY (1996) 14 PP 1574-8 *

Also Published As

Publication number Publication date
JP2001515493A (ja) 2001-09-18
AU6462998A (en) 1998-09-29
WO1998040508A1 (en) 1998-09-17
EP0973926A1 (en) 2000-01-26
US6613563B1 (en) 2003-09-02
US20040029280A1 (en) 2004-02-12
CA2283461A1 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
AU742365B2 (en) Adenoviral vectors with modified tropism
ES2246533T3 (es) Fibra adenovirica modificada y adenovirus dianas.
AU734515B2 (en) A short-shafted adenoviral fiber and its use
US6054312A (en) Receptor-mediated gene delivery using bacteriophage vectors
AU743051B2 (en) Gene transfer with adenoviruses having modified fiber proteins
US20020099024A1 (en) Chimeric adenovirus fiber protein
CZ162398A3 (cs) Vektory a způsoby pro genový přenos do buněk
HUP0200073A2 (hu) Célzott adenovírus vektorok heterológ gének beadására
MXPA99010682A (es) Vectores para la distribucion de genes, provistoscon tropismo de tejido para celulas de musculo liso y/o celulas endoteliales.
AU771686B2 (en) Adenoviral vectors with modified tropism
CA2527721A1 (en) Chimeric adenovirus capsid proteins
WO2009081154A1 (en) Targeted delivery of macromolecules
MXPA98004203A (en) Vectors and methods for gene transfer acelu
MXPA00002076A (en) Receptor-mediated gene delivery using bacteriophage vectors
HK1002284B (en) Novel implant and novel vector for the treatment of acquired diseases
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
AU2007200616A1 (en) Gene Transfer with Adenoviruses Having Modified Fiber Proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)